Upstream Bio's Verekitug Shows Promise in Asthma Control for CRSwNP Patients
Event summary
- Upstream Bio presented Phase 2 VIBRANT trial data at ATS 2026 showing verekitug improved asthma symptom control in CRSwNP patients with comorbid asthma.
- Verekitug reduced ACQ-6 scores by -0.9 (placebo-adjusted LSM) at Week 24, exceeding the minimal clinically important change of -0.5.
- The trial also demonstrated improvements in nasal polyp score (NPS) and reductions in type 2 inflammatory biomarkers in both blood and nasal secretions.
- Upstream Bio plans to initiate Phase 3 trials for CRSwNP and severe asthma in Q1 2027.
The big picture
Upstream Bio's verekitug targets the TSLP receptor, a clinically validated driver of inflammatory response in respiratory diseases. The positive Phase 2 data positions the drug as a potential new treatment option for patients with CRSwNP and comorbid asthma, addressing a significant unmet need in the market. The company's focus on severe respiratory disorders aligns with the growing demand for targeted therapies in this space.
What we're watching
- Regulatory Pathway
- Whether the Phase 2 endpoints will support regulatory submissions for product approval.
- Market Differentiation
- How verekitug's quarterly dosing interval and potential best-in-class efficacy will position it against existing biologics.
- Pipeline Progression
- The pace at which Upstream Bio advances verekitug into Phase 3 trials for CRSwNP and severe asthma.
Related topics